SGO 2022 Conference Coverage on VuMedi


 

SGO 2022 on a Phase 2 OVARIO Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Frontline PBC With Bevacizumab

289 views
April 1, 2022
Comments 0
Login to view comments. Click here to Login